Story

Bernstein Sees 33% Downside for Novo Nordisk, Cuts Forecasts on Eli Lilly Threat

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Bernstein Sees 33% Downside for Novo Nordisk, Cuts Forecasts on Eli Lilly Threat
Text size
Background

Bernstein has significantly lowered its long-term earnings forecasts for Novo Nordisk A/S (NOVOb), citing intensifying competition from rival Eli Lilly (LLY) in the U.S. market for GLP-1 drugs. The investment firm maintained its "Underperform" rating on the stock, projecting a potential 33% downside from its August 7 closing price.

Forecasts Slashed on Competitive Pressures

Analysts at the firm cut their adjusted earnings-per-share (EPS) estimates for the 2026-2031 period, placing them well below market consensus. The move was driven by expectations that Novo Nordisk will lose more market share than previously anticipated to Eli Lilly's injectable obesity and diabetes treatments in the United States.

Key forecast reductions include:

  • 2026 EPS Estimate: Lowered to 20.19 Danish kroner, which is 7% below the Bloomberg consensus of 21.74 kroner.
  • 2031 EPS Estimate: Cut to 24.20 Danish kroner, representing a 15% gap below the consensus of 28.31 kroner.

Bernstein also anticipates that Novo's forthcoming Wegovy Pill will lose majority share in the U.S. oral obesity market to Lilly’s competing drug, Foundayo, by 2028. The firm warned of worsening U.S. price deflation for GLP-1 drugs, which could lead to margin misses.

Sample IUX Markets – In-articleAd

Valuation and Pipeline Concerns

Despite raising its price target slightly to 203 Danish kroner from 200 kroner, Bernstein's valuation implies significant risk. The new target is 33% below the stock's 305.10 kroner close on August 7. The firm noted its bull/bear scenario analysis remains "negatively skewed," with a potential 4% upside versus a 40% downside to its 2035 operating profit estimates.

Analysts stated that "the catalyst cupboard looks bare" for Novo Nordisk. They highlighted that Cagri-sema, a key pipeline drug, is no longer viewed as a source of upside risk after its REDEFINE-4 trial failed to show non-inferiority to Lilly’s Zepbound in a February 2026 readout. The minor price target increase was attributed to new, below-consensus sales projections for coramitug, an antibody for a rare heart disease.

Market Pricing in 'Extreme' Growth

Bernstein's valuation is based on a discounted cash flow (DCF) model and an EV/EBITA multiples analysis, both of which apply a 30% discount to European pharmaceutical peers. The firm argued that the current share price implies a perpetuity growth rate of 5%, which it called "extreme" given the looming patent expiries for its key drug, semaglutide, between 2026 and 2032.

Read next

More on Stocks
Back to latest news

LATEST